Jackson Laboratory

The state's bioscience sector has developed a new strategic plan that aims to add 6,000-plus industry jobs over the next decade.

In his recent State of the State speech, Gov. Ned Lamont said: “What I love about America is that in every generation we get a chance to reinvent ourselves, and every election gives us a fresh start. This is our chance to reinvent Connecticut, to think big and act boldly.”

The latest biopharma industry downsizing has created new startup opportunities, but also cast uncertainty over the sector's future.

Farmington's Jackson Laboratory for Genomic Medicine and biotech firm Azitra Inc. said they won a $500,000 grant from the Pentagon to establish a program studying organisms that cause rare skins infections.

Medical science is a noble calling, but it's often extremely competitive, and the next batch of research funding is always top of mind.

The Jackson Laboratory for Genomic Medicine's personalized medicine facility in Farmington is now nearly debt free, at least as far as the state is concerned.

With reluctance, Gov. Dannel P. Malloy on Thursday inked legislation that provides a tax break for bioscience investors.

UConn Health's board of directors told lawmakers in a recent letter that a public-private partnership may be its best chance at long-term sustainability.

This past October, when Dawn Hocevar assumed her new role as president and CEO of CURE — Connecticut's membership association of bioscience companies — she brought more than her decades of experience in the sector to the state, she also brought a new name for the organization, BioCT.

The year 2018 could be a decisive one for the future of Farmington-based UConn Health, according to its CEO Dr. Andrew Agwunobi.